Anebulo Pharmaceuticals, Inc. ANEB
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -74.26%
- 1 year
- -89.72%
- Market cap
- 10.60M
- EPS (ttm)
- -0.19
- Shares out
- 25.93M
- Forward P/E
- -2.49
- YTD return
- -74.26%
- 1-year return
- -89.72%
- Volume
- 100
- Avg volume
- 185
- Open
- 0.8699
- Previous close
- 0.26
- Day's range
- 0.8699 – 0.8699
- 52-week range
- 0.001 – 2.54
- Beta
- -1.01
- Price target
- 8.00 (+2976.9%)
- Earnings date
- Feb 11, 2025
2Y -1.5800 (-85.87%)
Key statistics
- Enterprise value
- 36.32M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 11.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.18M
- Total cash
- 3.09M
- Total debt
- 0
- Return on equity
- -113.80%
- Short % of float
- 0.28%
- 50-day average
- 1.60
- 200-day average
- 2.14
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate -0.08.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.08 | — | — |
| Sep 25, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Sep 25, 2024 | Jun 1, 2024 | 0.00 | -0.05 | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.11 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.11 | -0.06 | +0.05 | +45.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Oct 1, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Oct 3, 2023 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Sep 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 21, 2023 | Maxim Group | init | — | Buy |
| Sep 18, 2023 | HC Wainwright & Co. | init | — | Buy |
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anebulo.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ANEB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ENGLISH ARON R | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Dec 17, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| 22NW, LP | 20.69% | 5,366,290 | 8.69M | Sep 29, 2024 |
| LVW Advisors, LLC | 2.47% | 641,039 | 1.04M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 1.97% | 511,073 | 827.94K | Sep 29, 2024 |
| Morgan Stanley | 1.54% | 399,219 | 646.73K | Sep 29, 2024 |
| Ikarian Capital, LLC | 0.61% | 157,862 | 255.74K | Sep 29, 2024 |
| Vanguard Group Inc | 0.59% | 154,036 | 249.54K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.47% | 121,000 | 196.02K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.21% | 53,431 | 86.56K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.13% | 33,036 | 53.52K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 14,728 | 23.86K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 11,840 | 19.18K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 4,108 | 6.65K | Oct 30, 2024 |